Casopitant

Drugbox
IUPAC_name = (2"S",4"S")-4-(4-Acetyl-1-piperazinyl)-"N"- [(1"R")-1- [3,5-bis(trifluoromethyl)phenyl] ethyl] -2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide

---

width = 220
CAS_number =
CAS_supplemental =
ATC_prefix =
ATC_suffix =
PubChem = 23725089
DrugBank =
C=30|H=35|F=7|N=4|O=2
molecular_weight = 616.26 g/mol
smiles = CC1=C(C=CC(=C1)F) [C@@H] 2C [C@H] (CCN2C(=O)N(C) [C@H] (C)C3=CC(=CC(=C3) C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
routes_of_administration =

Casopitant (INN) is an neurokinin 1 receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV). [cite journal |author=Lohr L |title=Chemotherapy-induced nausea and vomiting |journal=Cancer J |volume=14 |issue=2 |pages=85–93 |year=2008 |pmid=18391612 |doi=10.1097/PPO.0b013e31816a0f07 |url=] It is developed by GlaxoSmithKline and is likely to be marketed in the US as Rezonic and in the EU as Zunrisa.

References